Your session is about to expire
← Back to Search
Control-IQ 2.0 Alternate Target for Type 1 Diabetes
Study Summary
This trial will test a new tech to help people with type 1 diabetes manage their blood sugar safely and effectively.
- Type 1 Diabetes
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 85 Patients • NCT01970241Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a serious kidney problem or need to undergo hemodialysis.You have experienced severe low blood sugar more than once in the past 6 months and needed help to treat it.You have a condition that makes you bleed more easily, like hemophilia or another bleeding disorder.You are willing and able to eat specific meals as part of the study.You have had problems with your adrenal glands in the past.You have had more than one episode of a serious condition called diabetic ketoacidosis (DKA) in the past 6 months.You have a history of gastroparesis, a condition that affects how your stomach empties.You are taking any medicine to lower your blood sugar, except for metformin. Examples of these medicines include GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, and sulfonylureas.You have had an allergic reaction to Humalog or Novolog in the past.
- Group 1: Control-IQ 2.0 Alternate Target
- Group 2: Control-IQ 2.0 Standard Target
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research endeavor enlist those over the age of 45?
"This research effort is seeking individuals aged 2 to 80 who meet the trial's eligibility criteria. Notably, there are 218 experiments open for minors and 902 trials available for elderly patients."
Are there any opportunities for patient enrollment in this trial?
"A review of clinicaltrials.gov reveals that this particular medical study is not presently recruiting patients. It was first launched on January 30th 2023 and last revised on the 5th of January, 2023. Nonetheless, 1229 other trials are in search for participants as we speak."
What is the end goal of this experiment?
"Tandem Diabetes Care, Inc., the trial sponsor for this study, has set as its main objective to measure Number of diabetic ketoacidosis (DKA) events over a 6 week period. Additionally, they plan on assessing secondary outcomes such as CGM percent time <54 mg/dL during each study period; CGM percent time <70 mg/dL during each study period.; and lastly, quantifying CGM percent time 70-180 mg/dL throughout the course of their research."
Is this research open to new volunteers?
"This clinical trial is seeking 72 individuals with type 1 diabetes between the ages of 2 and 80. The potential participants must possess an HbA1c level lower than 10.5%, weigh at least 20 lbs, take a minimum of two units/day insulin, and have utilized Dexcom CGM for 11 or more days in the 14 prior to screening. Furthermore, those under 18 need to be accompanied by a parent or legal guardian knowledgeable about emergency hypoglycemia procedures during meals challenges as well as willing to use the Dexcom Follow app; adults over 18 require access to a local contact who meets similar qualifications. Lastly, all enrol"
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger